Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Immunoglobulin E receptor: Expression and regulation

The Immunoglobulin E receptor: Expression and regulation The interaction of immunoglobulin E (IgE) and its receptors is critical for the manifestation of allergic disease. Currently, IgE receptors include the high-affinity FcεRI and the lowaffinity FcεRII. FcεRI is a tetrameric or trimeric complex, and each has distinct expression patterns and unique functional consequences. In general, serum levels of IgE regulate FcεRI expression, and novel therapies that lower the concentration of IgE have provided insights into the contribution of this receptor in allergic disease. Newer therapies targeting FcεRI-signaling elements and the lowaffinity IgE receptor, FcεRII (CD23), are being developed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Allergy and Asthma Reports Springer Journals

The Immunoglobulin E receptor: Expression and regulation

Loading next page...
 
/lp/springer-journals/the-immunoglobulin-e-receptor-expression-and-regulation-QRlBo92Dw9

References (60)

Publisher
Springer Journals
Copyright
Copyright © 2005 by Current Science Inc
Subject
Medicine & Public Health; Allergology; Pneumology/Respiratory System; Otorhinolaryngology; Infectious Diseases
ISSN
1529-7322
eISSN
1534-6315
DOI
10.1007/s11882-005-0037-5
Publisher site
See Article on Publisher Site

Abstract

The interaction of immunoglobulin E (IgE) and its receptors is critical for the manifestation of allergic disease. Currently, IgE receptors include the high-affinity FcεRI and the lowaffinity FcεRII. FcεRI is a tetrameric or trimeric complex, and each has distinct expression patterns and unique functional consequences. In general, serum levels of IgE regulate FcεRI expression, and novel therapies that lower the concentration of IgE have provided insights into the contribution of this receptor in allergic disease. Newer therapies targeting FcεRI-signaling elements and the lowaffinity IgE receptor, FcεRII (CD23), are being developed.

Journal

Current Allergy and Asthma ReportsSpringer Journals

Published: May 27, 2005

There are no references for this article.